Plain-language issue guide

Healthcare, Prescription Drugs and Medicare

Healthcare, Prescription Drugs and Medicare follows reviewed filings coded for general health issues, pharmacy policy, or Medicare and Medicaid. It was selected because four different organizations bring distinct roles to the same policy area: a pharmaceutical company, a membership organization, and two companies with health-related federal matters. The current matches are distributed across the group, with Pfizer contributing the largest share but not a majority.

Data retrieved through Sep 4, 2026 · Content reviewed Sep 4, 2026

Editorial illustration representing healthcare, prescription drugs, and Medicare.

Gov Influence analytical brief

Bottom-line assessment

Gov Influence assessmentModerate confidence

Healthcare, Prescription Drugs and Medicare filing activity was distributed across 4 reviewed organizations, with no single organization accounting for half of the matches.

19 retained filings matched this issue group. Pfizer had the largest count at 8 (42%), and 4 organizations appeared in both quarters.

Evidence and reasoning

Reasoning: Gov Influence uses a transparent majority threshold: one organization must account for at least 50% of matched filings for the pattern to be called concentrated. The leading share is 42%; recurrence across both comparable quarters helps distinguish a sustained collection pattern from a single-quarter cluster. These measures describe filing distribution, not political importance, position, effort, or influence.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Healthcare, Prescription Drugs and Medicare.

Other plausible interpretation

  • Quarterly filing cadence, organization reporting structure, and the breadth of the official issue codes may shape the distribution; the selected six-organization, two-quarter collection does not establish a longer-term or Washington-wide pattern.

Method: issue-profile-assessment-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

The categories record disclosed subject matter and do not by themselves establish policy positions or effects on prices, access, coverage, or health outcomes.

Why this matters

What the pattern adds to the record

Health-related filing activity appears across all four represented organizations and both quarters, producing a distributed pattern whose specific drug, program, and benefit questions become visible in the source descriptions.

Supporting analysis

Key findings

Calculated from recordsHigh confidence

Healthcare, Prescription Drugs and Medicare combines 3 distinct official issue codes while preserving their original filing language.

Code-level filing counts are HCR: 17; PHA: 3; MMM: 7. These counts can overlap within one filing, and 14 matched filings also appear in another reviewed issue group.

Evidence and reasoning

Reasoning: Each official code is counted separately when it appears in a retained filing, so code totals and normalized issue groups may overlap. Original descriptions provide narrower subject detail, but neither a broad code nor specific wording establishes support, opposition, priority, or policy effect.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Healthcare, Prescription Drugs and Medicare.

Method: issue-code-language-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Calculated from recordsHigh confidence

4 reviewed organizations account for the 19 matched filings on this issue page.

Pfizer: 8; AARP: 5; Amazon: 4; Boeing: 2.

Evidence and reasoning

Reasoning: The calculation assigns each matched canonical filing to its reviewed organization identity, then orders counts by filing frequency with an alphabetical tie break. It is a distribution measure within the selected collection, not an influence score, sector ranking, or statement about a subject's political importance.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Healthcare, Prescription Drugs and Medicare.

Method: issue-organization-distribution-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Calculated from recordsHigh confidence

Healthcare, Prescription Drugs and Medicare matched filing counts changed between the reviewed quarters.

2026-Q1: 10 filings from 4 organizations; 2026-Q2: 9 filings from 4 organizations.

Evidence and reasoning

Reasoning: Each canonical filing is counted once within this issue group when at least one activity carries an included official code. Comparing the same selected organizations and adjacent reporting quarters measures filing frequency only; it does not establish increasing or decreasing political importance, effort, or effect.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Healthcare, Prescription Drugs and Medicare.

Method: issue-quarter-comparison-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Show 1 additional reviewed finding
Calculated from recordsHigh confidence

4 organizations recur across both quarters, and 6 reviewed outside firms appear in the matched filings.

Recurring organizations: Pfizer, AARP, Amazon, Boeing. Outside-firm counts use approved registrant identities and their supporting canonical filings.

Evidence and reasoning

Reasoning: An organization is counted as recurring only when at least one matched canonical filing appears in each quarter. A firm is counted only when a matched filing carries an approved outside-firm registrant identity and client relationship. Recurrence and disclosed firm-client structure do not establish coordination, access, position, or results.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Healthcare, Prescription Drugs and Medicare.

Method: issue-recurrence-relationships-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Focused starting collection

Why this is in the initial collection

This issue shows why a policy area should be read across unlike organizations rather than assumed from an organization's industry alone. Pfizer and AARP provide expected health-policy perspectives, while Boeing and Amazon demonstrate how health categories also appear in broader organizational filing sets. Keeping HCR, PHA, and MMM separate lets visitors compare general health, pharmacy, and public-program reporting before reading the filer-specific detail.

What this edition covers: The analysis counts retained Q1 and Q2 2026 filings from four organizations when an activity uses HCR, PHA, or MMM.

Questions this page helps answer

  • Which organizations appear in the health-policy records?
  • How do Health Issues, Pharmacy, and Medicare/Medicaid differ?
  • What narrower topics appear in the filing language?
Site calculation

How the matched filings compare by quarter

Each retained filing is counted once on this issue page even when it carries more than one included code.

Matched organizations and filings during 2026 Q1 and 2026 Q2
Reporting quarterOrganizationsFilings
2026 Q1410
2026 Q249

14 of this page’s 19 filing matches also appear in at least one other issue group. A filing can report several official codes, so issue totals must not be added as if they were unique records.

How the selected organizations compare

This comparison counts filing matches within the six-organization collection. Longer bars mean more matched filings here, not more influence or policy importance.

Matched filing count by organization during 2026 Q1 and 2026 Q2
AARP5
Amazon4
Boeing2
Pfizer8
Exact matched filing counts
OrganizationTotal2026 Q12026 Q2
AARP532
Amazon422
Boeing211
Pfizer844
Show separately reported amount context for these filing matches

Amounts apply to whole organization filings, which can cover matters outside this issue group. Self-reported expenses and outside-firm income have different reporting bases and are never added together.

Filing-level amount context, kept separate by reporting basis
OrganizationQuarterFilingsSelf-reported expensesOutside-firm income
AARP2026-Q13$3,830,000$70,000
AARP2026-Q22no applicable records$70,000
Amazon2026-Q12$4,380,000$80,000
Amazon2026-Q22$4,360,000$80,000
Boeing2026-Q11$2,450,000no applicable records
Boeing2026-Q21$2,770,000no applicable records
Pfizer2026-Q14$4,420,000$270,000
Pfizer2026-Q24$1,880,000$270,000

Reviewed filing relationships

Outside firms appearing with this issue

These profiles appear because a retained filing uses this issue group's reviewed official code and identifies the firm's approved LDA registrant ID. A shared code does not establish a policy position, coordination, or effect.

Context, not causation

Why these records and guides are connected

Organization links come from this issue group’s reviewed filing codes. Bill links require an explicit matched-activity reference, a separately approved subject link, or a reviewed classification based on the bill’s official title, policy area, or subjects. None of these connections proves influence, support, opposition, or effect.

Organizations represented in the matched filings

Reviewed code match

See AARP’s reviewed lobbying profile

5 retained filings from 2026 Q1 and 2026 Q2 use at least one code in this issue group. That count does not establish a policy position or outcome.

Reviewed code match

See Amazon’s reviewed lobbying profile

4 retained filings from 2026 Q1 and 2026 Q2 use at least one code in this issue group. That count does not establish a policy position or outcome.

Reviewed code match

See Boeing’s reviewed lobbying profile

2 retained filings from 2026 Q1 and 2026 Q2 use at least one code in this issue group. That count does not establish a policy position or outcome.

Reviewed code match

See Pfizer’s reviewed lobbying profile

8 retained filings from 2026 Q1 and 2026 Q2 use at least one code in this issue group. That count does not establish a policy position or outcome.

Legislative context

Explore why S 1818 appears with this issue

The reviewed bill classification uses the official title, policy area, or subjects to place this bill in the same browsing topic. Reviewed classification based on the official Health policy area and bill title; it does not state a position on the bill. This is a record connection, not a causal claim.

Show the source records for this connection

Legislative context

Explore why S 4946 appears with this issue

The reviewed bill classification uses the official title, policy area, or subjects to place this bill in the same browsing topic. Reviewed classification based on the official title’s health-data and privacy wording and the Commerce policy area; it does not state a position on the bill. This is a record connection, not a causal claim.

Show the source records for this connection
Lobbying disclosure

Official code mapping and original source wording

The summary above uses broad official Lobbying Disclosure Act (LDA) categories. Open these details to inspect the full mapping and examples in the filer’s own words.

Show all included codes and the classification boundary

A normalized Gov Influence group for reviewed filings that use HCR, PHA, or MMM. Source descriptions may state narrower subtopics, but the page does not infer a position from those terms.

Official source codes included in this issue group
Code and official labelPlain distinctionOrganizationsFilingsActivities
HCR — Health IssuesHealth Issues records41717
PHA — PharmacyPharmacy records233
MMM — Medicare/MedicaidMedicare/Medicaid records377

Included

  • Include a retained filing once when any activity reports HCR, PHA, or MMM.
  • Keep Health Issues, Pharmacy, and Medicare/Medicaid activities separated by their official source code.

Excluded

  • Do not include a filing merely because an organization operates in healthcare or serves older adults.
  • Generic references to benefits, consumers, budgets, or government programs are too broad without a reviewed HCR, PHA, or MMM activity.

Classification method: Only filings carrying the reviewed Health Issues, Pharmacy, or Medicare/Medicaid LDA issue codes enter this grouping.

Read representative original filing descriptions

One reproducible example is selected for each included code by organization name and filing ID. The examples preserve source wording and are not a ranking.

HCR · AARP · 2026 Q2

Rural healthcare access issues for seniors

PHA · AARP · 2026 Q1

S. 1040, the Drug Competition Enhancement Act. S. 1041, the Affordable Prescriptions for Patients Act. S. 2620, the Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act. S. 2658, the Medication Affordability and Patent Integrity Act. S. 1095, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act. S. 1784/H.R. 4191, the Mapping America's Pharmaceutical Supply Act or the MAPS Act. No bill number. Lifetime prescription drug price increases. No bill number. Discussed Medicare drug price negotiation. No bill number. Discussed Medicare Part D. No bill number. Discussed international reference pricing. No bill number. Discussed prescription drug supply chain vulnerabilities. No bill number. Discussed Most Favored Nation prescription drug model and GLOBE model. No bill number. Discussed Medicare Part D/ Most Favored Nation prescription drug model, GUARD. No bill number. Discussed pharmacy benefit manager reforms. No bill number. Discussed proposed Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. No bill number. Discussed prescription drugs.

MMM · AARP · 2026 Q1

S. 3439/H.R. 6735, Connecting Caregivers to Medicare Act. S. 1227/H.R. 2491, Alleviating Barriers for Caregivers Act. P.L. 119-21, the One Big Beautiful Bill Act. H.R. 6766/S. 3492, the Essential Caregivers Act. H.R. 7966/S. 4118, Hospice Care Accountability, Reform, and Enforcement (Hospice CARE) Act. H.R. 7618, Stopping Addiction and Falls for the Elderly (SAFE) Act. S. 2237/H.R. 4313, Hospital Inpatient Services Modernization Act. H.R. 8100, Safe Staffing Saves Lives Act. S. 3886, Nurses Belong in Nursing Homes Act. H.R. 7966/S. 4118, Hospice Care Accountability, Reform, and Enforcement (Hospice CARE) Act. S. 3886, Nurses Belong in Nursing Homes Act. No bill number. Discussed Medicare payment models. No bill number. Discussed Medicare waste, fraud, and abuse. No bill number. Discussed health technology, data security, enrollee accounts, and access. No bill number. Discussed Medicaid and waste, fraud, and abuse. No bill number. Discussed Medicaid community engagement requirements and Data Strategy for Family Caregiver Verification. No bill number. Discussed nursing home staffing standards, safety, and quality. No bill number. Discussed nursing home transparency and ownership requirements. No bill number. Discussed home health, hospice, and long-term care. No bill number. Discussed Medicare Advantage. No bill number. Discussed the Medicare Prescription Drug Benefit Program. No bill number. Discussed the Medicare Cost Plan Program. No bill number. Discussed Medicare Advantage Capitation Rates. No bill number. Discussed Medicare Part C and Part D payment policies. No bill number. Discussed Medicare Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). No bill number. Discussed AI tools for Medicare Experience modernization. No bill number. Discussed Medicare Advantage provider networks. No bill number. Discussed fraud in Medicare and Medicaid. No bill number. Discussed long-term services and supports. No bill number. Discussed home and community-based services. No bill number. Discussed the Money Follows the Person Rebalancing Demonstration Program. No bill number. Discussed Medicaid home and community-based services (HCBS) spousal impoverishment protections. No bill number. Discussed the direct care workforce. No bill number. Discussed family caregiver exemption from Medicaid community engagement requirements. No bill number. Discussed falls prevention. No bill number. Discussed age-friendly communities. No bill number. Discussed health at home. No bill number. Discussed the National Strategy to Support Family Caregivers. No bill number. Discussed the Older Americans Act reauthorization. No bill number. Discussed Medicaid HCBS waivers. No bill number. Discussed the health care workforce.

Sources and interpretation

What this page cannot show

  • Whether an organization favored or opposed a health, drug, Medicare, or Medicaid policy.
  • Patient, price, access, coverage, or health-outcome effects.
  • Healthcare activity outside the selected records and reporting period.
  • Code matches, descriptions, timing, organizations, reported amounts, and bill references do not establish influence, coordination, motive, wrongdoing, or causation.
Show all 19 matched source records